PMID- 33062726
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20220417
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2020
DP  - 2020
TI  - Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients 
      with Chemotherapy-Resistant Metastatic Osteosarcoma.
PG  - 7890985
LID - 10.1155/2020/7890985 [doi]
LID - 7890985
AB  - BACKGROUND: The pathological subtype of osteosarcoma is one of the most common 
      malignant bone tumors. Notably, chemotherapy-resistant metastatic osteosarcoma 
      has been reported to cause significant mortality and shows poor prognosis with 
      the currently available multidisciplinary treatments. This study investigated 
      whether combined adoptive TIL and anti-PD1 therapy improves the prognosis of 
      patients with chemotherapy-resistant metastatic osteosarcoma. METHODS: A total of 
      60 patients with chemotherapy-resistant metastatic osteosarcoma between June 2016 
      and March 2018 were enrolled. The primary endpoint was to evaluate the safety and 
      adverse effects (AEs) of infusions of TIL and anti-PD1 therapy in the patients. 
      Besides, secondary endpoints included assessing the objective response rate 
      (ORR), progression-free survival time (PFS), and overall survival time (OS). 
      RESULTS: We reported that combined TIL therapy and anti-PD1 therapy is safe and 
      all treatment-related AEs were reversible or manageable. The ORR of all the 
      patients is 36.67%, and patients with more infusions of TIL and CD8(+)TIL, less 
      infusions of CD8(+)PD1(+)TIL, and less infusion of CD4(+)FoxP3(+)TIL exhibited 
      increased PFS and OS. CONCLUSION: This study determined that combined TIL and 
      anti-PD1 therapy is safe and effective in metastatic osteosarcoma patients with 
      chemotherapy resistance.
CI  - Copyright (c) 2020 Xiang Zhou et al.
FAU - Zhou, Xiang
AU  - Zhou X
AD  - Department of Orthopedic Surgery, Luoyang Central Hospital Affiliated to 
      Zhengzhou University, Luoyang 471009, China.
FAU - Wu, Junlong
AU  - Wu J
AD  - Department of Orthopedic Surgery, Luoyang Central Hospital Affiliated to 
      Zhengzhou University, Luoyang 471009, China.
FAU - Duan, Chunguang
AU  - Duan C
AD  - Department of Orthopedic Surgery, Shenzhen University General Hospital, Shenzhen 
      518055, China.
FAU - Liu, Yingjie
AU  - Liu Y
AUID- ORCID: 0000-0001-5391-7996
AD  - Department of Orthopedic Surgery, Luoyang Central Hospital Affiliated to 
      Zhengzhou University, Luoyang 471009, China.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Interleukin-2)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Bone Neoplasms/immunology/mortality/*therapy
MH  - Combined Modality Therapy
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*therapeutic use
MH  - Immunotherapy, Adoptive/*methods
MH  - Interleukin-2/metabolism
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Neoplasm Metastasis
MH  - Nivolumab/*therapeutic use
MH  - Osteosarcoma/immunology/mortality/*therapy
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Young Adult
PMC - PMC7547340
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this paper.
EDAT- 2020/10/17 06:00
MHDA- 2021/07/13 06:00
PMCR- 2020/10/01
CRDT- 2020/10/16 05:56
PHST- 2020/02/25 00:00 [received]
PHST- 2020/05/26 00:00 [revised]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/10/16 05:56 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - 10.1155/2020/7890985 [doi]
PST - epublish
SO  - J Immunol Res. 2020 Oct 1;2020:7890985. doi: 10.1155/2020/7890985. eCollection 
      2020.